Benzinga · Jul 15, 2026
Stereotaxis Files Prospectus Related To Resale Of 108.87M Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1289340/000149315226033398/forms-3.htm
ST
AMEX · STXS
Stereotaxis, Inc.
Healthcare · Medical - Instruments & Supplies
$0.86
Down-$0.05 (-5.21%)
Updated Oct 31, 2026, 6:47 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 224.53M
- P/E ratio
- -9.28
- Dividend yield
- 0.00%
- 52-week range
- $0.81 – $2.89
- Volume
- 1.44M
- Avg. volume
- 552.95K
Price performance · STXS
STXS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
STXS closed at $0.86 after 21 trading sessions, down 26.90% for the selected period.
- Last close
- $0.86
- Period change
- -26.90%
- Period low
- $0.86
- Period high
- $1.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.90 | $0.9183 | $0.8101 | $0.8626 | 1.44M |
| Oct 29, 2026 | $0.95 | $0.9985 | $0.91 | $0.91 | 812.86K |
| Oct 28, 2026 | $1.04 | $1.04 | $0.9698 | $0.9703 | 309.54K |
| Oct 27, 2026 | $0.9912 | $1.04 | $0.9853 | $1.03 | 565.95K |
| Oct 26, 2026 | $1.03 | $1.03 | $0.9862 | $0.99 | 328.79K |
| Oct 23, 2026 | $0.994 | $1.04 | $0.994 | $1.02 | 421.22K |
| Oct 22, 2026 | $0.9819 | $1.03 | $0.9819 | $0.998 | 381.71K |
| Oct 21, 2026 | $0.9942 | $1.04 | $0.98 | $0.9949 | 615.33K |
| Oct 20, 2026 | $1.01 | $1.03 | $0.98 | $0.9983 | 637.38K |
| Oct 19, 2026 | $0.9934 | $1.05 | $0.95 | $1.01 | 889.68K |
| Oct 16, 2026 | $1.06 | $1.07 | $1.00 | $1.01 | 870.06K |
| Oct 15, 2026 | $1.04 | $1.06 | $1.02 | $1.05 | 641.35K |
| Oct 14, 2026 | $1.04 | $1.05 | $1.03 | $1.05 | 692.26K |
| Oct 13, 2026 | $1.13 | $1.14 | $1.05 | $1.06 | 964.55K |
| Oct 12, 2026 | $1.11 | $1.16 | $1.08 | $1.14 | 461.4K |
| Oct 9, 2026 | $1.11 | $1.12 | $1.09 | $1.11 | 419.47K |
| Oct 8, 2026 | $1.12 | $1.13 | $1.09 | $1.11 | 560.47K |
| Oct 7, 2026 | $1.13 | $1.145 | $1.115 | $1.13 | 338.19K |
| Oct 6, 2026 | $1.18 | $1.21 | $1.13 | $1.15 | 873.44K |
| Oct 5, 2026 | $1.18 | $1.20 | $1.17 | $1.18 | 505.23K |
| Oct 2, 2026 | $1.22 | $1.22 | $1.18 | $1.18 | 344.41K |
Latest STXS news
The latest Smart Investors Daily articles mentioning STXS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
STXS research
Overview
Company profile and research snapshot.
Company profile
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Citizens | Market Outperform | — |
| Aug 12, 2026 | TD Cowen | Buy | — |
| May 13, 2026 | Piper Sandler | Overweight | — |
| Dec 16, 2025 | Citizens | Market Outperform | — |
| Nov 12, 2025 | Roth Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 9, 2026
Stereotaxis Launches New Robotic Electrophysiology Program At Klinikum Fürth In Fürth, Germany
Yahoo · Jan 14, 2026
da Vinci 5 Expands Globally: Can ISRG Beat Overseas Cost Hurdles?
ISRG's da Vinci 5 begins international rollout, but pricing sensitivity, budgets, and reimbursement hurdles could slow adoption outside the United States.
Yahoo · Jan 7, 2026
Stereotaxis wins FDA approval for robotically navigated ablation catheter
Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
